Industry Insiders – Georgie Lutz

We were thrilled to chat with our dear friend, and one of our industry's long-standing veterans Georgie Lutz. With experience dating back to the industry's early days, Georgie has been at the forefront of patient care, having previously held key operational and clinical leadership roles at NCC Clinics and Lyphe Australia. Most recently, she co-founded the independent Bosman Clinic alongside Dr. Manus Bosman with one clear, uncompromising vision to put patients first.

In this post, Georgie shares her unique insights on how the medicinal cannabis landscape has evolved, the current challenges of commercialisation, and why transparency, education, and clinical independence are crucial for the industry's next phase of growth.

As one of the long-standing leaders in the medicinal cannabis sector, to now co-founding Bosman Clinic with Dr. Manus Bosman — how have you seen the industry evolve since its early days, and what changes have been the most significant?

The industry has evolved dramatically since I first entered the space in 2017. In the early days access was incredibly limited, products were expensive, and patients had to jump through multiple administrative hurdles just to be considered eligible for treatment. Fast forward to today, and the landscape looks completely different. Regulatory pathways have matured, approval timeframes have significantly reduced, and prescribing has become far more streamlined.

One of the most significant changes has been the normalisation of medicinal cannabis within healthcare. Increased market participation has driven costs down considerably, making treatment more accessible to a broader patient population. Ultimately, the most meaningful change has been accessibility, the industry’s evolution has moved us closer to balancing access with safety.

From your perspective, how has the patient landscape and the brand and product ecosystem changed over time, and what trends are you seeing today?

The brand and product ecosystem has evolved just as dramatically as the regulatory side. Today, the market is saturated, with hundreds of SKUs. One of the biggest trends we’re seeing is the rise of closed-loop or vertically integrated clinic models. Yet, one of the most consistent complaints of patients is feeling restricted to specific brands aligned with commercial arrangements. As such, as the market matures, there is a risk of becoming brand-led rather than patient-led.

However, on the positive side, product quality, consistency and transparency have improved significantly. Patients have more choices than ever before. Yet, the challenge now is ensuring that expanded choice genuinely benefits patients rather than being filtered through commercial gatekeeping.

Looking ahead, where would you like to see the medicinal cannabis industry move in the next few years, and what needs to happen to ensure patient needs remain the top priority?

I would like to see the industry firmly anchored in a genuinely patient-led model. Long-term sustainability depends on keeping patient outcomes and clinical integrity at the centre of decision-making. Additionally, greater regulatory consistency across states would significantly improve efficiency and reduce administrative burden for patients, pharmacists and prescribers alike.

Further, I believe the next phase should focus on quality over volume. That means stronger governance within clinics, clearer separation between prescribing decisions and commercial arrangements, and continued education for healthcare professionals. Transparency is critical, and patients should understand their options and be able to trust that their treatment plan is based on medical appropriateness as opposed to potential commercial agreements.

What advice would you give to new market entrants—whether clinics, brands, or product companies—as well as to existing players currently operating in the space?

The barrier to entry in medicinal cannabis has lowered significantly, but long-term sustainability requires discipline and differentiation. For brands and product companies, simply launching another similar product is unlikely to build longevity. Brands need to offer clear value and a distinct point of difference.

For clinics, operational integrity and scalability are critical from day one. For existing operators, the next phase will reward transparency and sustainability over aggressive short-term growth. Patients are becoming more informed and selective. As such, clinics and brands that prioritise trust, operational excellence and clinical credibility will outlast those focused purely on expansion.

Tell us about the Bosman Clinic: what inspired its creation, what gap were you hoping to fill, and what is the long-term vision for the clinic?

Bosman Clinic was created with one simple principle — put the patient first. Meaning, no closed-loop ecosystems and no restricting patients based on commercial arrangements. Patients deserve transparency, autonomy, and a voice in their treatment decisions. Further, we also wanted to strengthen governance and good clinical practice. A key part of our long-term vision is education — mentoring and training new doctors in good prescribing practices and regulatory compliance. On a patient level, our focus is approachability and trust. We are also passionate about supporting smaller Australian-led brands. We are not focused on being the biggest clinic in Australia, to us longevity and integrity matter more than rapid expansion.

In your view, what will define the next phase of growth for the medicinal cannabis industry in Australia, and what key challenges still need to be addressed to get there?

The next phase of growth in Australia will be defined by maturity rather than expansion. The rapid growth stage has already occurred — now the focus must shift to governance, consistency and long-term credibility.

Greater regulatory harmonisation across states would provide stability for prescribers and patients. Maintaining a clear separation between commercial models and clinical decision-making will also be critical. Education will play an important role, particularly in supporting new prescribers. If the industry can balance access, regulation and commercial sustainability while keeping patient care at the centre, medicinal cannabis will continue integrating more confidently into mainstream healthcare.

You can check out Bosman Clinic’s website here as well as Georgie’s and Dr Hermanus Bosman’s Linkedin profiles.

Learn More

EQWELLIBRIYUM offers end-to-end consulting for organisations navigating the medicinal cannabis market in Australia. With strategic insights and operational frameworks that are designed to help you thrive, we’re here to help you. Learn more by contacting us today at hello@eqwellibriyum.com or signing up to our email list below.